重组人血小板生成素治疗难治性原发免疫性血小板减少症的临床观察  

Efficacy Observation of Recombinant Human Thrombopoietin for Refractory Primary Immune Thrombocytopenia

作　　者：魏巍[1] 艾丽梅[2] 陶彩芳[1] 李雁[1] 

机构地区：[1]辽宁医学院附属第三医院血液科,辽宁锦州121000 [2]辽宁医学院附属第一医院血液科,辽宁锦州121001

出　　处：《中国药房》2012年第32期3012-3014,共3页China Pharmacy

摘　　要：目的:观察重组人血小板生成素(rhTPO)治疗难治性原发免疫性血小板减少症的疗效及安全性。方法:30例难治性原发免疫性血小板减少症患者皮下注射rhTPO 300U.kg-1.d-1,疗程≤14 d,至血小板计数升至≥100×109个/L。治疗期间注意动态监测用药后的血小板计数、肝肾功能及凝血时间。结果:30例患者用药前血小板计数为(14.17±6.74)×109个/L,用药后第14天为(132.03±70.37)×109个/L,治疗前、后比较差异有统计学意义(P<0.01)。另外,30例患者中完全反应23例,有效6例。仅2例患者出现轻度嗜睡及头晕,但均能耐受,且停药后消失;其余患者未见明显不良反应发生。结论:rhTPO治疗难治性原发免疫性血小板减少症疗效显著,不良反应轻微。OBJECTIVE： To observe the efficacy and ADR of recombinant human thrombopoietin （rhTPO） in the treatment of refractory primary immune thrombocytopenia. METHODS： 30 patients with refractory primary immune thrombocytopenia were ad- ministered with 300 U.kg-1 rhTPO subcutaneously once daily for 14 days at most or until the platelet count increased to 100×109/L. The platelet count, the function of liver and kidney and coagulation function were monitored. RESULTS： The platelet count （132.03 ± 70.37）× 109/L 14 days after treatment was significantly greater than the platelet count （14.17 ± 6.74）× 109/L before treat- ment （P〈0.01）. There were 23 patients in the group with completely response and 6 patients in the response group. Slight hyper- somnia and dizziness occurred in only 2 patients and they disappeared after withdrawal of rhTPO. No ADR was found in other patients. CONCLUSION： rhTPO has satisfactory efficacy in the treatment of refractory primary immune thrombocytopenia with slight ADR.

关 键 词：重组人血小板生成素 难治性 免疫性血小板减少症 

分 类 号：R558.2[医药卫生—血液循环系统疾病] R554.6[医药卫生—内科学]